

PTO/SB/21 (02-04)

The Thirty of the Control of the Con		U.S. Pater	it and Trademark Office	e; U.S. D	igh 07/31/2006. OMB 0651-0031 DEPARTMENT OF COMMERCE
Under the Habet Work Reduction Act of 1995.	no persons	s are required to respond to a collection Application Number	10/821,828	S II GISDI	avs a valid OMB control humber.
TRANSMITTAL		Filing Date	April 9, 2004		
FORM		First Named Inventor	Hector F. DeLuca et al		
(to be used for all correspondence after initial t	filing)	Art Unit	1616		
		Examiner Name			
Total Number of Pages in This Submission		Attorney Docket Number	1256-00949		
	ENCL	LOSURES (Check all that	t apply)		
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)  Extension of Time Request  Express Abandonment Request		Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence Addr  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)	ess to App of App (App Pro	After Allowance communication to Technology Center (TC)  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information	
SIGNA	TURE O	F APPLICANT, ATTORN	EY, OR AGEN	ſ	
Thomas M. Wozny, Reg. No. 28,922 Individual name Andrus: Sceales, Starker& Sawal, LLP Signature  Date  August 24, 2004					
CI	ERTIFIC	CATE OF TRANSMISSION	I/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Typed or printed name Dorothy A. Hauser					
Signature Date August 24, 2004					August 24, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.	:	10/821,828	)	CERTIFICATE OF MAILING
Applicant	:	Hector F. DeLuca et al	)	I hereby certify that this correspondence is
			)	being deposited with the United States
Filed	:	April 9, 2004	)	Postal Service with sufficient postage as
Title	:	2-Alkylidene-18,19-	)	first class mail in an envelope addressed
		Dinor-Vitamin D	)	to: Commissioner of Patents, P.O. Box
		Compounds	)	1450, Alexandria, VA 22313-1450, on
			)	this 24th day of August, 2004.
TC/A.U.	:	1616	)	
Examiner	:		)	$A \cap A \cap A$ .
			)	Absorby (I Musel August 24, 2004)
Docket No.	. :	1256-00949	)	Dorothy A. Hauser Date

## INFORMATION DISCLOSURE STATEMENT

Mail Stop: No Fee

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references listed on the enclosed PTO Form 1449 are being submitted in the above-identified patent application in accordance with 37 CFR 1.97(b)(3).

A copy of each of the non-U.S. patent references is enclosed in compliance with the rules.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP

Thomas M. Wozny

Reg. No. 28,922

Andrus, Sceales, Starke & Sawall, LLP 100 East Wisconsin Avenue, Suite 1100

By

Milwaukee, WI 53202 Telephone: (414) 271-7590 Facsimile: (414) 271-5770

Form PTO-1449

INFORMATION DISCLOSURE STAT

U.S. Department of Commerce Patent and Trademark Office Atty. Docket No. 1256-00949

Appln. No.: 10/821,828

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Hector F. DeLuca et al

Filing Date

April 9, 2004

Group Art Unit 1616

	U.S. PATENT DOCUMENTS					
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF PPROPRIATE
	6,392,071	05-21-2002	DeLuca et al			
	5,945,410	08-31-1999	DeLuca et al			
	5,936,133	08-10-1999	DeLuca et al			
	5,877,168	03-02-1999	Miyamoto et al			
	5,843,928	12-01-1998	DeLuca et al			
	5,843,927	12-01-1998	DeLuca			
	5,817,648	10-06-1998	Kutner et al			
	5,756,489	05-26-1998	DeLuca et al			
	5,721,225	02-24-1998	DeLuca et al			
	5,587,497	12-24-1996	DeLuca et al			
	5,536,713	07-16-1996	DeLuca et al			
	5,246,925	09-21-1993	DeLuca et al			
	5,237,110	08-17-1993	DeLuca et al			
	5,086,191	02-04-1992	DeLuca et al			
	4,666,634	05-19-1987	Miyamoto et al			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSI Yes	LATION No
	EP0184206	12-04-1985	Europe				
	EP0078704	04-29-1987	Europe				
	EP0387077	09-03-1990	Europe				
	EP0474517	11-03-1992	Europe				
	EP0480572	04-15-1992	Europe				

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 1256-00949	Appln. No.: 10/821,828	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Hector F. DeLuca et al		
		Filing Date April 9, 2004	Group Art Unit 1616	

	EP0516410	12-02-1992	Europe		
	WO90/09991	09-07-1990	PCT		
	WO96/01811	01-25-1996	PCT		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)					
Baggiolini et al, "Stereochemical Total Synthesis of 1α,25- Dihydroxycholecalciferol and 1β,25-Dihydroxyerocalciferol", Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.					
Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D <sub>3</sub> ", Bioactivity of 19-Nor-Pre D, Vol. 8, No. 8, pp. 1009-1015, 1993.					
Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.					
Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.					
Fujishima et al, "Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1α,25-Dihydroxyvitamin D <sub>3</sub> ," Bioorganic & Medicinal Chemistry Letters, 8, pp. 2145-2148, 1998.					
Kiegiel et al, "Chemical Conversion of Vitamin D <sub>3</sub> to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, Vol. 31, No. 43, pp. 6057-60660, 1991.					
Konno et al, "A Novel and Practical Route to A-Ring Enyne Synthon for 1α,25-Dihydroxyvitamin D <sub>3</sub> Analogs: Synthesis of A-ring Diastereomers of 1α,25-Dihydroxy-Vitamin D <sub>3</sub> and 2-Methyl-1,25-Dihydroxyvitamin D <sub>3</sub> ," Bioorganic & Medicinal Chemistry Letters, 8, pp. 151-156, 1998.					
Okano et al, "Regulatory Activities of 2β-(3-Hydroxypropoxy)-1α,25-Dihydroxyvitamin D <sub>3</sub> . A Novel Synthetic Vitamin D <sub>3</sub> Derivative on Calcium Metabolism", Biochemical and Biophysical Research Communications, Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.					
Perlman et al, "1α,25-Dihydroxy-19-Nor-Vitamin D <sub>3</sub> . A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, Vol. 31, No. 13, pp. 1823-1824, February 1990.					

	nent of Commerce Trademark Office Atty. Docket No. 1256-00949	Appln. No.: 10/821,828		
INFORMATION DISCLOSURE STATEMENT BY AI (Use several sheets if necessary)	Applican	Applicant Hector F. DeLuca et al		
	Filing Date April 9, 2004	Group Art Unit 1616		

Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.
Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1α,2α,25-Trihydroxyvitamin D <sub>3</sub> ", Journal of Organic Chemistry, 56, pp. 4339-4341, April 15, 1995.
Sarandeses et al, "Synthesis of 1α,25-Dihydroxy-19-Norprevitamin D <sub>3</sub> ", Tetrahedron Letters, pp. 5445-5448, April 1992.
Sicinski et al, "New 1α,25-Dihydroxy-19-Norvitamin D <sub>3</sub> Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues," Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.
Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH) <sub>2</sub> D <sub>2</sub> Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", American Journal of Kidney Disorders, 26(5), 832-60, 1995.
Suhara et al, "Synthesis and Biological Evaluation of Novel 2α-Substituted 1α,25-Dihydroxyvitamin D <sub>3</sub> Analogues," Biolorganic & Medicinal Chemistry Letters, 10, pp. 1129-1132, March 16, 2000.

EXAMINER	DATE CONSIDERED
*Examiner: Initial if reference considered, whether or not citation is in conformance v	with MPEP 609; Draw line through citation if not in

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to client.